Radiochemical separation of no-carrier-added as produced via the process

Lebedev, N.A.; Novgorodov, A.F.; Misiak, R.; Βrockmann, J.; Rösch, Frank

doi:10.1016/s0969-8043(99)00284-5

Cited by 82 publications

(40 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the indirect route, 177 Lu is produced as the decay product of the short-lived 177 Yb, which is produced by neutron capture of enriched 176 Yb27. Despite the fact that no-carrier added 177 Lu is produced in this process, the high cost of enriched 176 Yb and the radiochemical separation of 177 Lu from the 176 Yb target are limiting its application282930. The direct route produces 177 Lu by neutron capture of enriched 176 Lu with clinically required specific activity at a lower cost3132.…”

Section: Discussionmentioning

confidence: 99%

Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects

Bhardwaj

Meer

Das

et al. 2017

Sci Rep

View full text Add to dashboard Cite

177Lu has sprung as a promising radionuclide for targeted therapy. The low soft tissue penetration of its β− emission results in very efficient energy deposition in small-size tumours. Because of this, 177Lu is used in the treatment of neuroendocrine tumours and is also clinically approved for prostate cancer therapy. In this work, we report a separation method that achieves the challenging separation of the physically and chemically identical nuclear isomers, 177mLu and 177Lu. The separation method combines the nuclear after-effects of the nuclear decay, the use of a very stable chemical complex and a chromatographic separation. Based on this separation concept, a new type of radionuclide generator has been devised, in which the parent and the daughter radionuclides are the same elements. The 177mLu/177Lu radionuclide generator provides a new production route for the therapeutic radionuclide 177Lu and can bring significant growth in the research and development of 177Lu based pharmaceuticals.

show abstract

Section: Discussionmentioning

confidence: 99%

Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects

Bhardwaj

Meer

Das

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In order to tap the potential of the electrochemical method, Lebedev et al reported a method [80] that essentially consists Fig. 8 Secondary NCA 177 Lu separation step [68].…”

Section: Cementation Processmentioning

confidence: 99%

Production of 177Lu for Targeted Radionuclide Therapy: Available Options

Dash

Pillai²,

Knapp

2015

Nucl Med Mol Imaging

239

166

View full text Add to dashboard Cite

Background: This review provides a comprehensive summary of the production of 177 Lu to meet expected future research and clinical demands. Availability of options represents the cornerstone for sustainable growth for the routine production of adequate activity levels of 177 Lu having the required quality for preparation of a variety of 177 Lu-labeled radiopharmaceuticals. The tremendous prospects associated with production of 177 Lu for use in targeted radionuclide therapy (TRT) dictate that a holistic consideration should evaluate all governing factors that determine its success. Methods: While both "direct" and "indirect" reactor production routes offer the possibility for sustainable 177 Lu availability, there are several issues and challenges that must be considered to realize the full potential of these production strategies. Results: This article presents a mini review on the latest developments, current status, key challenges and possibilities for the near future. Conclusion: A broad understanding and discussion of the issues associated with 177 Lu production and processing approaches would not only ensure sustained growth and future expansion for the availability and use of 177 Lu-labeled radiopharmaceuticals, but also help future developments.

show abstract

“…1,4,7-triazacyclononane-N,N′N″-triacetic acid (NOTA) and its analogues of [10]-N 3 and [12]-N 3 rings (Fig. 1) were synthesized by the reaction of triaza rings with bromoacetic acid, according to the method described by Takahashi and Takamato [28].…”

Section: Reagentsmentioning

confidence: 99%

“…However, this indirect route of production requires a difficult radiochemical separation of 177 Lu from the irradiated Yb 2 O 3 target. Taking into account that ytterbium and lutetium are neighbouring trivalent lanthanides and the mass ratio Yb/Lu in the irradiated target can be as high as several thousand, separation is a very difficult task [10][11][12].…”

Section: Introductionmentioning

confidence: 99%